ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01618136
Recruitment Status : Completed
First Posted : June 13, 2012
Last Update Posted : November 16, 2016
Sponsor:
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Limited )

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2015
  Actual Study Completion Date : July 2015